RG

Ravi Goyal

Active Director Director DIN 03563786
DIN 03563786 First appointment Jul 2011 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2011
Shareholding value •••• Premium profile

About Ravi Goyal

Data last updated:

Ravi Goyal is a Director at Pci Bioscience Private Limited (since 2011). The company operates in Pharma. Pci Bioscience Private Limited reported revenue of ₹73.1 Lakh (FY 2024).

DIN 03563786
Primary Designation Director
Industry Pharma
First Appointment 28 Jul 2011
Oldest Company Age 15 yrs
Largest company Pci Bioscience Private Limited · ₹73.1 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Pci Bioscience Private Limited U24100HR2011PTC043514
Director28 Jul 20112011₹73.1 Lakh (FY 2024)Active

Board colleagues of Ravi Goyal

NameDINCompanyDesignation
Bishamber Goyal03465824Pci Bioscience Private LimitedDirector

Directorship timeline

Open interactive timeline →
Pci Bioscience Private Limited
Premium access

Shareholding and investment profile for Ravi Goyal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ravi Goyal

Ravi Goyal currently holds 1 directorship: Pci Bioscience Private Limited (Director, since 28 Jul 2011, revenue ₹73.1 Lakh (FY 2024)).

Ravi Goyal was first appointed on 28 Jul 2011 as Director at Pci Bioscience Private Limited.

The current boards of Ravi Goyal's companies include Bishamber Goyal (Pci Bioscience Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available